Patents by Inventor Anders Erik BERGLUND

Anders Erik BERGLUND has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE GENE SIGNATURES IN MUSCLE INVASIVE BLADDER CANCER
    Publication number: 20230323468
    Abstract: This invention relates to methods for selecting a treatment and optionally treating subjects with muscle-invasive bladder cancer based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: August 27, 2021
    Publication date: October 12, 2023
    Inventors: Roger Li, James J. Mulé, Anders Erik Berglund
  • Immune gene signatures in urothelial carcinoma (UC)
    Patent number: 10583183
    Abstract: This invention relates to methods for treating subjects with bladder cancer, such as urothelial carcinoma, based on mRNA expression levels of chemokines.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: March 10, 2020
    Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Anthony M. Magliocco, James J. Mulé, Anders Erik Berglund
  • Immune Gene Signatures in Urothelial Carcinoma (UC)
    Publication number: 20170175199
    Abstract: This invention relates to methods for selecting a treatment, treating, and predicting survival time in subjects with cancer, such as colorectal cancer, based on tumor expression levels of chemokines, cytotoxic genes, and/or dendritic cell genes.
    Type: Application
    Filed: April 10, 2015
    Publication date: June 22, 2017
    Inventors: Anthony M. MAGLIOCCO, James J. MULE, Anders Erik BERGLUND